Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab

The development of checkpoint inhibitors has changed the treatment paradigm for cancer. Checkpoint inhibitors nivolumab, pembrolizumab, and cemiplimab target programmed death-1 (PD-1), whereas durvalumab, avelumab, and atezolizumab target PD-ligand 1. Ipilimumab targets cytotoxic T lymphocyte–associ...

Descripción completa

Detalles Bibliográficos
Autores principales: Bukamur, Hazim, Katz, Heather, Alsharedi, Mohamed, Alkrekshi, Akram, Shweihat, Yousef R., Munn, Nancy J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Medicine & Medical Specialties
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7587235/
https://www.ncbi.nlm.nih.gov/pubmed/33140115
http://dx.doi.org/10.14423/SMJ.0000000000001166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7587235/
https://www.ncbi.nlm.nih.gov/pubmed/33140115
http://dx.doi.org/10.14423/SMJ.0000000000001166

Ejemplares similares